Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy

Abstract Recently, associations between the biomarker galectin-3 and numerous pathological processes involved in heart failure (HF) and right ventricular (RV) function have been observed. We aimed to assess the long-term prognostic ability of galectin-3 and RV function parameters for all-cause morta...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Beata Zaborska, Ewa Pilichowska-Paszkiet, Ewa Makowska, Grażyna Sygitowicz, Tomasz Słomski, Michał Zaborski, Andrzej Budaj
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/82c7bf981ddb478c8842fdb4b87f2ae3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:82c7bf981ddb478c8842fdb4b87f2ae3
record_format	dspace
spelling	oai:doaj.org-article:82c7bf981ddb478c8842fdb4b87f2ae32021-11-08T10:50:22ZPrognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy10.1038/s41598-021-00984-22045-2322https://doaj.org/article/82c7bf981ddb478c8842fdb4b87f2ae32021-11-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-00984-2https://doaj.org/toc/2045-2322Abstract Recently, associations between the biomarker galectin-3 and numerous pathological processes involved in heart failure (HF) and right ventricular (RV) function have been observed. We aimed to assess the long-term prognostic ability of galectin-3 and RV function parameters for all-cause mortality in HF patients treated with cardiac resynchronization therapy (CRT). We prospectively studied 63 symptomatic HF patients with a left ventricular (LV) ejection fraction (EF) ≤ 35%. The median serum galectin-3 concentration was 13.4 ng/mL (IQR 11.05, 17.15). A detailed assessment of LV and RV geometry and function was performed with echocardiography. CRT defibrillator implantation was achieved in all patients without major complications. The follow-up lasted 5 years. In the multivariable Cox regression model, independent predictors for all-cause mortality were log baseline galectin-3 and baseline RV function expressed as tricuspid annular plane systolic excursion with HR 2.96 (p = 0.037) and HR 0.88 (p = 0.023), respectively. Analysis of subgroups defined by galectin-3 concentration and CRT response showed that patients with high baseline galectin-3 concentrations and a lack of response to CRT had a significantly lower probability of survival. In our patient cohort, the baseline galectin-3 concentration and RV function were independent predictors of long-term all-cause mortality in HFrEF patients following CRT implantation.Beata ZaborskaEwa Pilichowska-PaszkietEwa MakowskaGrażyna SygitowiczTomasz SłomskiMichał ZaborskiAndrzej BudajNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Beata Zaborska Ewa Pilichowska-Paszkiet Ewa Makowska Grażyna Sygitowicz Tomasz Słomski Michał Zaborski Andrzej Budaj Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy
description	Abstract Recently, associations between the biomarker galectin-3 and numerous pathological processes involved in heart failure (HF) and right ventricular (RV) function have been observed. We aimed to assess the long-term prognostic ability of galectin-3 and RV function parameters for all-cause mortality in HF patients treated with cardiac resynchronization therapy (CRT). We prospectively studied 63 symptomatic HF patients with a left ventricular (LV) ejection fraction (EF) ≤ 35%. The median serum galectin-3 concentration was 13.4 ng/mL (IQR 11.05, 17.15). A detailed assessment of LV and RV geometry and function was performed with echocardiography. CRT defibrillator implantation was achieved in all patients without major complications. The follow-up lasted 5 years. In the multivariable Cox regression model, independent predictors for all-cause mortality were log baseline galectin-3 and baseline RV function expressed as tricuspid annular plane systolic excursion with HR 2.96 (p = 0.037) and HR 0.88 (p = 0.023), respectively. Analysis of subgroups defined by galectin-3 concentration and CRT response showed that patients with high baseline galectin-3 concentrations and a lack of response to CRT had a significantly lower probability of survival. In our patient cohort, the baseline galectin-3 concentration and RV function were independent predictors of long-term all-cause mortality in HFrEF patients following CRT implantation.
format	article
author	Beata Zaborska Ewa Pilichowska-Paszkiet Ewa Makowska Grażyna Sygitowicz Tomasz Słomski Michał Zaborski Andrzej Budaj
author_facet	Beata Zaborska Ewa Pilichowska-Paszkiet Ewa Makowska Grażyna Sygitowicz Tomasz Słomski Michał Zaborski Andrzej Budaj
author_sort	Beata Zaborska
title	Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy
title_short	Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy
title_full	Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy
title_fullStr	Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy
title_full_unstemmed	Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy
title_sort	prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/82c7bf981ddb478c8842fdb4b87f2ae3
work_keys_str_mv	AT beatazaborska prognosticvalueofgalectin3andrightventricularfunctionforlongtermmortalityinheartfailurepatientstreatedwithcardiacresynchronizationtherapy AT ewapilichowskapaszkiet prognosticvalueofgalectin3andrightventricularfunctionforlongtermmortalityinheartfailurepatientstreatedwithcardiacresynchronizationtherapy AT ewamakowska prognosticvalueofgalectin3andrightventricularfunctionforlongtermmortalityinheartfailurepatientstreatedwithcardiacresynchronizationtherapy AT grazynasygitowicz prognosticvalueofgalectin3andrightventricularfunctionforlongtermmortalityinheartfailurepatientstreatedwithcardiacresynchronizationtherapy AT tomaszsłomski prognosticvalueofgalectin3andrightventricularfunctionforlongtermmortalityinheartfailurepatientstreatedwithcardiacresynchronizationtherapy AT michałzaborski prognosticvalueofgalectin3andrightventricularfunctionforlongtermmortalityinheartfailurepatientstreatedwithcardiacresynchronizationtherapy AT andrzejbudaj prognosticvalueofgalectin3andrightventricularfunctionforlongtermmortalityinheartfailurepatientstreatedwithcardiacresynchronizationtherapy
_version_	1718442633367388160

Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy

Ejemplares similares